Capricor Theraputics Q4 revenue falls to zero, net loss widens

Capricor Therapeutics

12/03/2026 20:31

Overview

U.S. biotech reported Q4 revenue of $0, down from prior year as milestone revenue fully recognized

Q4 net loss widened yr/yr on higher operating expenses

Company ended 2025 with $318 mln cash, expects runway through 2027

Outlook

Capricor expects cash balance to support operations through 2027

Company expanding manufacturing capacity in anticipation of potential Deramiocel approval

Result Drivers

REVENUE DECLINE - Co said Q4 revenue fell to zero as all milestone and upfront payments from Nippon Shinyaku were fully recognized by end-2024

Cash, cash equivalents and marketable securities totaled approximately $318.1 million as of December 31, 2025

HIGHER OPERATING EXPENSES - Co attributed increased Q4 operating expenses to ongoing clinical development, regulatory activities, and commercial launch preparations

Company press release: ID:nGNX27Zfp8

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.62
Q4 Net Income
-$30.20 mln
Q4 Basic EPS
-$0.62
Q4 Operating Expenses
$29.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Capricor Therapeutics Inc is $50.00, about 48.9% above its March 11 closing price of $33.57

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)